MagPro R20
Our customers can always expect the highest quality
Researchers and clinicians often use MagVenture’s products in combination with products from other manufacturers. Our products are highly integrable with the solutions offered by Localite (neuronavigation), Brain Products (EEG) and Axilum Robotics (TMS Robots)
The MagPro R20 is a magnetic stimulator intended as an electro-physiological aid to assess and monitor the central and peripheral nervous systems. A diagnostic tool to measure motor evoked potential (MEP) in clinical examinations and for therapeutic use. It can be applied for treatment with standard 10 Hz or 15 Hz protocols. The device is compatible with a wider range of coils than the MagPro Compact and is ideal for clinics running a limited number of TMS sessions per day. CE approved and FDA cleared for treatment for major depressive disorder.Quick and easy to set up.
features
| Max repetition rate | 20 pps |
| Pulse mode | Standard |
| Waveform | Biphasic |
| Current direction | Normal |
| Ramp up | No |
Specifications
Mechanical Data
| HxWxD | 150 x 390 x 440mm/ 5,9 x 15,3 x 17,3 in |
| Weight | 20 kg/ 44 lbs |
Coil compatibility
| These coils can be used to operate the MagPro R20: C-100, C-B60, MC-B70, MC-125, MMC-90, MMC-140, MMC-140-II, RT-120, RT-120-II, D-B80, MC-B65-HO, MCF-B65, MCF-B70, MCF-75, MCF-125, MCF-P-B65, MC-P-B70, MCF-P-B70 |
Environmental Data
| Operating temperature | 10-30°C/50-86°F |
| Storage temperature | 5-50°C/41-122°F |
| Operating humidity | 30-60% RH |
| Storage humidity | 20-80% RH |
Power Supply
| Mains voltage | 230V~,50/60 Hz according to IEC 60601-1 |
| Maximum power consumption | 800 VA, operation from 100V~ or 120V~ through transformer |
Ordering number
| 9016E0861 |
Applications
Intended use
Diagnostic Use
The MagPro R20 is intended as an electro-physiological aid to assess diagnosis and to monitor diseases of the central and peripheral nervous system, based on the use of Motor Evoked Potentials (MEP).
Therapeutic Use
Treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode.
